Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$200K
Filings
42
Firms Hired
3
Active Period
2008–2018
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement; development of policies to advance the antimicrobial research and development environment. Support for H.R. 6294 - REVAMP Act.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 6294
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement; development of policies to advance the antimicrobial research and development environment. Support for H.R. 6294 - REVAMP Act.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6294
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement; development of policies to advance the antimicrobial research and development environment. Support for H.R. 6294 - REVAMP Act.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6294
FDA Reauthorization Act of 2017
2017 · third_quarter · Firm: THE MCMANUS GROUP
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement; development of policies to advance the antimicrobial research and development environment. Food and Drug Administration legislative and regulatory issues. Advocated to include market incentives for antimicrobials in H.R. 2430 / S. 934 - FDA Reauthorization Act of 2017.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 2430
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement; development of policies to advance the antimicrobial research and development environment. Food and Drug Administration legislative and regulatory issues. Advocated to include market incentives for antimicrobials in H.R. 2430 / S. 934 - FDA Reauthorization Act of 2017.
Client expense: — · Firm income: $30,000
Matched citations: S. 934
FDA Reauthorization Act of 2017
2017 · second_quarter · Firm: THE MCMANUS GROUP
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement; development of policies to advance the antimicrobial research and development environment. Food and Drug Administration legislative and regulatory issues. Advocated to include market incentives for antimicrobials in H.R. 2430 / S. 934 - FDA Reauthorization Act of 2017.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 2430
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement; development of policies to advance the antimicrobial research and development environment. Food and Drug Administration legislative and regulatory issues. Advocated to include market incentives for antimicrobials in H.R. 2430 / S. 934 - FDA Reauthorization Act of 2017.
Client expense: — · Firm income: $30,000
Matched citations: S. 934
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement; Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015" language in - H.R.6 - 21st Century Cures Act.; Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $30,000
Matched citations: H.R.512
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement; Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015" language in - H.R.6 - 21st Century Cures Act.; Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $30,000
Matched citations: H.R.6
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement; Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015" language in - H.R.6 - 21st Century Cures Act.; Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $30,000
Matched citations: H.R.512
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement; Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015" language in - H.R.6 - 21st Century Cures Act.; Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $30,000
Matched citations: H.R.6
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement; Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015" language in - H.R.6 - 21st Century Cures Act.; Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $50,000
Matched citations: H.R.512
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement; Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015" language in - H.R.6 - 21st Century Cures Act.; Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $50,000
Matched citations: H.R.6
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement; Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015" language in - H.R.6 - 21st Century Cures Act.; Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $50,000
Matched citations: H.R.512
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement; Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015" language in - H.R.6 - 21st Century Cures Act.; Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $50,000
Matched citations: H.R.6
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement; Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015" language in - H.R.6 - 21st Century Cures Act.; Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $50,000
Matched citations: H.R.512
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement; Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015" language in - H.R.6 - 21st Century Cures Act.; Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $50,000
Matched citations: H.R.6
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement; Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015" language in - H.R.6 - 21st Century Cures Act.; Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $50,000
Matched citations: H.R.512
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement; Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015" language in - H.R.6 - 21st Century Cures Act.; Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $50,000
Matched citations: H.R.6
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement; Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015" language in - H.R.6 - 21st Century Cures Act.; Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $50,000
Matched citations: H.R.512
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement; Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015" language in - H.R.6 - 21st Century Cures Act.; Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $50,000
Matched citations: H.R.6
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement; Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015" language in - H.R.6 - 21st Century Cures Act.; Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $50,000
Matched citations: H.R.512
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement; Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015" language in - H.R.6 - 21st Century Cures Act.; Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $50,000
Matched citations: H.R.6
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement, H.R.512 - "DISARM Act of 2015"; Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $50,000
Matched citations: H.R.512
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement, H.R.4187 - "DISARM Act of 2014"; Food and Drug Administration legislative and regulatory issues.
Client expense: — · Firm income: $50,000
Matched citations: H.R.4187
Source: Senate LDA